Restart Life Sciences (TSE:HEAL)
:HEAL
Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume800.00
Average Volume (3M)3.65K
Market Cap
C$3.66M
Enterprise ValueC$3.57M
Total Cash (Recent Filing)C$1.65M
Total Debt (Recent Filing)C$245.36K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,550,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Equity In 2025Turning to positive equity in 2025 indicates the company has rebuilt net worth after prior deficits. That structural restoration reduces immediate insolvency risk, improves creditor and investor confidence, and meaningfully increases financing flexibility for multi-month strategic initiatives.
Modest Leverage In 2025Low debt relative to equity in 2025 reduces fixed interest obligations and refinancing pressure, preserving cash for R&D or operations. Structurally lower leverage gives management optionality and lowers the probability that capital structure constraints will force distress or cutbacks over the next several months.
Improving Cash Outflow TrendOperating and free cash outflows have materially moderated versus trough years, showing a durable improvement in burn rate. If sustained, this trend lengthens runway, reduces near-term external funding needs and gives management time to execute strategic milestones without immediate liquidity stress.
Bears Say
No Recurring Revenue (2021–2025)A complete absence of recurring revenue over multiple years means the business lacks an established commercial revenue base. Structurally, this forces dependence on financing to sustain operations, makes profitability timelines uncertain, and increases execution risk around product commercialization.
Persistent Operating Losses & Negative FCFOngoing operating losses with negative free cash flow indicate the company cannot self-fund operations or growth. Over months this necessitates repeated external capital, increasing dilution risk, constraining long-term investment, and leaving strategic plans contingent on access to financing.
Historic Negative Equity & VolatilityPrior episodes of negative equity signal past solvency pressure and financial instability. That history can impair lender and partner confidence, raise cost of capital, and increase the likelihood of restrictive covenants or tougher financing terms, limiting strategic flexibility over months.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$3.66M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Jun 02, 2026 which is in 30 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 36,550,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Technical Analysis
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---